Roche news

ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone

Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1.

Roche reports further accelerated sales growth in third quarter

Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets ; Genentech integration progressing successfully; New Group leadership appointed

Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer

A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin).

Continuous improvements in animal welfare within Roche Research

Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation.

From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases

New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer:
Combination of Avastin with standard chemotherapy resulted in shrinkage or disappearance of liver metastases in 78% of patients with advanced colon cancer. A third of patients

Roche announces results from two early studies which show promise for patients with malignant melanoma

New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor

Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer

Analysis of BRAIN study shows that patients may have a stabilisation or improvement in neurocognitive function and a reduction in steroid use.

Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal flu

53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients.
Rate of death was reduced by 37% in high-risk patients with severe seasonal flu compared with no treatment

Roche Media News

The latest media news from Roche

Syndicate content